Alseres Pharmaceuticals, Inc.
ALSE · OTC
6/30/2014 | 3/31/2014 | 12/31/2013 | 9/30/2013 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $46 | $94 | $114 | $27 |
| Short-Term Investments | $148 | $185 | $207 | $24 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $7 | $9 | $10 | $0 |
| Total Curr. Assets | $220 | $305 | $325 | $75 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $59 | $60 | $61 | $62 |
| Total NC Assets | $59 | $60 | $61 | $62 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $279 | $364 | $385 | $137 |
| Liabilities | – | – | – | – |
| Payables | $0 | $500 | $500 | $696 |
| Short-Term Debt | $119 | $0 | $0 | $6,685 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $74 | $74 | $74 | $74 |
| Other Curr. Liab. | $10 | $12 | $13 | $75 |
| Total Curr. Liab. | $1,811 | $1,690 | $1,648 | $10,199 |
| LT Debt | $8,297 | $8,129 | $7,820 | $0 |
| Deferred Rev, NC | $1,106 | $1,124 | $1,143 | $1,161 |
| Deferred Tax Liab, NC | $401 | $396 | $390 | $0 |
| Other NC Liab. | $1,150 | $1,168 | $1,187 | $16,419 |
| Total NC Liab. | $9,847 | $9,693 | $9,397 | $17,580 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $11,658 | $11,383 | $11,045 | $27,779 |
| Equity | – | – | – | – |
| Pref Stock | $401 | $396 | $390 | $385 |
| Common Stock | $306 | $306 | $306 | $306 |
| Retained Earnings | -$200,288 | -$199,967 | -$199,635 | -$199,874 |
| AOCI | -$49 | -$14 | $7 | -$35 |
| Other Equity | $0 | $0 | $0 | $0 |
| Total Equity | -$11,379 | -$11,018 | -$10,660 | -$27,642 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $279 | $364 | $385 | $137 |
| Net Debt | $8,369 | $8,035 | $7,706 | $6,658 |